Netherlands Oncology Therapeutics Market Report 2022 to 2030

Netherlands Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Netherlands Oncology Therapeutics Market will reach a value of $934 Mn from $472 Mn in 2022, growing at a CAGR of 8.9% during 2022-30. The Oncology Therapeutics Market in the Netherlands is dominated by a few domestic pharmaceutical companies such as Kiadis Pharma, AM-Pharma, and Vico Therapeutics. The Oncology Therapeutics Market in the Netherlands is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Netherlands Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10NLPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Vishwa Modhia

Buy Now

Netherlands Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Netherlands Oncology Therapeutics Market will reach a value of $934 Mn from $472 Mn in 2022, growing at a CAGR of 8.9% during 2022-30.

The Netherlands is a high-income, developed constituent country located in Western Europe and with territories in the Caribbean. In the Netherlands, while 56,000 people were diagnosed with cancer in 1989, by 2019 this had risen to 118.000. people in the Netherlands are more likely to have cancer than people in almost all other European countries. In comparison to other European countries, melanoma and colon cancer are more common in men and women in the Netherlands. Data from the Dutch Cancer Registry and Statistics Netherlands (CBS) shows that, in 2019, 117,631 people were diagnosed with a form of cancer. 22.600 of those diagnoses were for skin cancer, with over 17.000 for breast cancer, and 13.800 for lung cancer.

The population-based Dutch cancer registry collects information on all patients newly diagnosed with cancer in the Netherlands. The Dutch government is devoted to the programme "smoke-free initiative." The Netherlands' government spent 11.1% of its GDP on healthcare in 2020.

Netherlands Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The Dutch government's goal is for no one to start smoking by 2040. Several strategies have been implemented to achieve this goal. if palliative care specialists are required, there are 14 ESMO-designed integrated cancer and palliative care centres (with this number, the Netherlands ranks fourth in Europe). The improved infrastructure and living standards in the Netherlands are a plus. the effects of an ageing population and unhealthy lifestyles on the overall health of the population of the Netherlands, and found that the number of people who have or have had cancer will rise from 800.000 in 2022 to a shocking 1,4 Mn by 2032, or approximately one in every 13 people These aspects could boost Netherlands Oncology Therapeutics Market.

Market restraints

There are 79 hospitals (in all, 109 locations), with seven of them being university medical centres, only one being a cancer centre, and the rest being large teaching hospitals. As the population ages, the Dutch pension system is under strain. The frequency of robotic-assisted thoracic surgery operations is not increasing, which could be explained in part by the related financial expenditures per procedure and the lack of proof of superiority compared to VATS. Numerous hurdles lie ahead, including the growing requirement to justify reimbursement for novel therapies and diagnostic tests, the continuation of smoke-free policies, and the need to obtain legislation to begin lung cancer screening. These factors may deter new entrants into the Netherlands Oncology Therapeutics Market.

Competitive Landscape

Key Players

Merus - Merus is a Dutch biotechnology company that specializes in the development of bispecific antibodies for the treatment of cancer. They have a pipeline of oncology therapeutics, including drugs for treating solid tumours and haematological malignancies
Kiadis Pharma - Kiadis Pharma is a Dutch biopharmaceutical company that focuses on the development of cell-based immunotherapy products for the treatment of cancer. They have a range of oncology products, including drugs for the treatment of acute myeloid leukaemia (AML) and graft-versus-host disease (GvHD)
AM-Pharma - AM-Pharma is a Dutch biopharmaceutical company that specializes in the development of therapeutic proteins for the treatment of acute kidney injury and cancer. They have a pipeline of oncology therapeutics, including drugs for the treatment of pancreatic cancer and colorectal cancer
ISA Pharmaceuticals - ISA Pharmaceuticals is a Dutch biotechnology company that focuses on the development of immunotherapies for the treatment of cancer. They have a pipeline of oncology therapeutics, including drugs for treating head and neck cancer and cervical cancer
Vico Therapeutics - Vico Therapeutics is a Dutch biopharmaceutical company that specializes in the development of RNA-based therapeutics for the treatment of rare genetic diseases and cancer

Recent Notable Updates

September 2022: European researchers from the Netherlands announced that a new treatment for advanced melanoma was more effective than the leading existing therapy in Phase 3 clinical trial. The treatment, which uses a patient’s own immune cells to fight cancer, has some similarities to another type of treatment that has proven to be highly effective for blood cancers, called CAR-T therapy.

Healthcare Policies and Reimbursement Scenarios

In the Netherlands, the administrative body responsible for endorsing and checking oncology therapeutics is the Medicines Evaluation Board (MEB). Concerningly, the Netherlands has a public medical coverage scheme known as the Health Insurance Act (Zvw). The Zvw takes care of the expense of most oncology therapies for its selected individuals, including chemotherapy, radiation treatment, and designated treatment. The Dutch government has carried out different drives to further develop access to oncology therapeutics in the nation, including the "Public Disease Plan," which means to further develop malignant growth inhibition, early identification, treatment, and aftercare.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the Netherlands Oncology Therapeutics market will reach a value of $934 Mn from $472 Mn in 2022, growing at a CAGR of 8.9% during 2022-2030.

In the Netherlands, the administrative body responsible for endorsing and checking oncology therapeutics is the Medicines Evaluation Board (MEB).

The Oncology Therapeutics Market in the Netherlands is dominated by a few domestic pharmaceutical companies such as Kiadis Pharma, AM-Pharma, and Vico Therapeutics.